Erasca enters its pan-RAS era
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
Revolution gets selective
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
FDA red and green lights: April 2025
April saw a checkpoint inhibitor bonanza for Bristol and Akeso.
Astra stumbles again with Truqap
The CAPItello-280 castrate-resistant prostate cancer trial is discontinued early.
AACR 2025 – Boehringer still has broad zongertinib hopes
Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.
AACR 2025 – Revolution shows lung promise
But half the responses with the KRAS G12D inhibitor zoldonrasib are unconfirmed.
